Clinical Trials Browser

Muscle Invasive Bladder Urothelial Carcinoma

NCT05150236 2023-12-15

ANZUP2001

Phase 2 Unknown

93 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Phase 2/3 Unknown

135 enrolled

Genitourinary

Prostatic Neoplasms

NCT03529890 2022-10-20

RACE IT

Phase 2 Unknown

33 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04913025 2022-09-21

REFINE

Phase 2 Unknown

160 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT03993249 2022-03-23

Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

Phase 2 Unknown

78 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03219775 2021-11-03

TITAN-TCC

Phase 2 Unknown

169 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03040791 2021-08-26

ImmunoProst

Phase 2 Unknown

38 enrolled

Genitourinary

Prostatic Neoplasms

NCT04142931 2021-03-24

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Phase 1 Unknown

30 enrolled

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

NCT04134182 2020-12-23

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Phase 2 Unknown

8 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

Drug Screening Using IMD in Bladder Cancer

ANZUP2001

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Microbiome Immunotherapy Toxicity and Response Evaluation

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

RACE IT

REFINE

Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

TITAN-TCC

ImmunoProst

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.